pe0139

PE0139 is a novel, super-long-acting basal insulin designed for the treatment of hyperglycemia associated with diabetes, particularly type 2 diabetes mellitus. It consists of a fully mature, native insulin molecule genetically fused to an elastin-like polypeptide (ELP) biopolymer using recombinant technology. This fusion extends the half-life of insulin, enabling once-weekly subcutaneous dosing by providing prolonged exposure and a flat pharmacokinetic profile with low peak-to-trough ratio. In clinical studies, PE0139 demonstrated dose-related reductions in fasting plasma glucose and was well tolerated without serious adverse events or hypoglycemia. Nonclinical models showed that PE0139 provided longer blood glucose reduction than standard basal insulins like insulin glargine and exhibited synergistic effects when combined with GLP-1 receptor agonists such as PB1023. The drug was developed by PhaseBio Pharmaceuticals but its development for type 2 diabetes mellitus was discontinued after phase II trials[1][2][4][5][7].

Brand names

insumera

Other names

insumerape 0139pe0139pe-0139